Assertio Holdings Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Assertio Holdings's earnings have been declining at an average annual rate of -12.6%, while the Pharmaceuticals industry saw earnings declining at 0.2% annually. Revenues have been declining at an average rate of 3.1% per year.
Belangrijke informatie
-12.6%
Groei van de winst
30.7%
Groei van de winst per aandeel
Pharmaceuticals Groei van de industrie | 6.0% |
Inkomstengroei | -3.1% |
Rendement op eigen vermogen | -261.1% |
Nettomarge | -261.1% |
Volgende winstupdate | 11 Nov 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Is Assertio Holdings (NASDAQ:ASRT) Using Debt Sensibly?
Sep 25Assertio Holdings, Inc. (NASDAQ:ASRT) Not Doing Enough For Some Investors As Its Shares Slump 30%
Aug 19There's No Escaping Assertio Holdings, Inc.'s (NASDAQ:ASRT) Muted Revenues Despite A 36% Share Price Rise
Jul 04Assertio Holdings, Inc. (NASDAQ:ASRT) Stock Catapults 29% Though Its Price And Business Still Lag The Industry
May 07Does Assertio Holdings (NASDAQ:ASRT) Have A Healthy Balance Sheet?
Apr 18Improved Revenues Required Before Assertio Holdings, Inc. (NASDAQ:ASRT) Stock's 26% Jump Looks Justified
Mar 13We Think Assertio Holdings (NASDAQ:ASRT) Can Stay On Top Of Its Debt
Apr 26Is There An Opportunity With Assertio Holdings, Inc.'s (NASDAQ:ASRT) 23% Undervaluation?
Mar 02Assertio Holdings Looks Good To Rebound After Recent Price Plunge
Sep 07Assertio Holdings: Substantial Upside
Aug 21Assertio Therapeutics Q2 2022 Earnings Preview
Aug 05Assertio Holdings: Management Still Swimming Against The Tide
Jun 10Assertio's Phenomenal Turnaround
May 19Assertio Holdings: Recent Breakout To Lead To Sustained Gains
Apr 07Assertio's Digital Strategy Looks To Be Paying Off
Jan 21Assertio shares rise on Q1 revenue strength, provides FY forecast
May 07Opbrengsten en kosten
Hoe Assertio Holdings geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
---|---|---|---|---|
30 Jun 24 | 132 | -345 | 81 | 4 |
31 Mar 24 | 142 | -333 | 71 | 4 |
31 Dec 23 | 152 | -332 | 70 | 3 |
30 Sep 23 | 169 | -186 | 60 | 2 |
30 Jun 23 | 168 | 98 | 55 | 1 |
31 Mar 23 | 162 | 97 | 55 | 0 |
31 Dec 22 | 156 | 110 | 48 | 0 |
30 Sep 22 | 139 | 26 | 35 | 0 |
30 Jun 22 | 130 | 25 | 41 | 0 |
31 Mar 22 | 121 | 3 | 43 | 0 |
31 Dec 21 | 111 | -1 | 46 | 0 |
30 Sep 21 | 110 | -30 | 69 | 0 |
30 Jun 21 | 119 | -44 | 75 | 2 |
31 Mar 21 | 114 | -65 | 90 | 3 |
31 Dec 20 | 108 | -28 | 104 | 4 |
30 Sep 20 | 135 | -196 | 106 | 10 |
30 Jun 20 | 156 | -183 | 116 | 10 |
31 Mar 20 | 192 | -162 | 113 | 9 |
31 Dec 19 | 230 | -217 | 110 | 10 |
30 Sep 19 | 157 | -49 | 111 | 7 |
30 Jun 19 | 180 | -4 | 108 | 7 |
31 Mar 19 | 186 | -11 | 116 | 8 |
31 Dec 18 | 256 | 37 | 120 | 8 |
30 Sep 18 | 364 | 28 | 143 | 7 |
30 Jun 18 | 381 | -36 | 160 | 7 |
31 Mar 18 | 419 | -42 | 179 | 10 |
31 Dec 17 | 381 | -102 | 203 | 14 |
30 Sep 17 | 410 | -114 | 203 | 22 |
30 Jun 17 | 425 | -111 | 205 | 30 |
31 Mar 17 | 442 | -95 | 206 | 32 |
31 Dec 16 | 456 | -89 | 205 | 33 |
30 Sep 16 | 443 | -75 | 194 | 30 |
30 Jun 16 | 437 | -74 | 192 | 24 |
31 Mar 16 | 415 | -85 | 197 | 22 |
31 Dec 15 | 343 | -76 | 179 | 18 |
30 Sep 15 | 426 | 50 | 170 | 13 |
30 Jun 15 | 373 | 68 | 148 | 10 |
31 Mar 15 | 346 | 102 | 123 | 7 |
31 Dec 14 | 390 | 132 | 121 | 7 |
30 Sep 14 | 236 | 79 | 119 | 7 |
30 Jun 14 | 222 | 79 | 119 | 7 |
31 Mar 14 | 185 | 67 | 112 | 7 |
31 Dec 13 | 134 | 43 | 105 | 8 |
Kwaliteitswinsten: ASRT is currently unprofitable.
Groeiende winstmarge: ASRT is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: ASRT is unprofitable, and losses have increased over the past 5 years at a rate of 12.6% per year.
Versnelling van de groei: Unable to compare ASRT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: ASRT is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.4%).
Rendement op eigen vermogen
Hoge ROE: ASRT has a negative Return on Equity (-261.15%), as it is currently unprofitable.